Apollo Hospitals has reported another strong quarter, with profit rising 32% and revenue growing 23%. But the most interesting part of these results is not simply the increase in earnings. It is how the company’s hospital, pharmacy and digital healthcare businesses are growing together.

Consolidated revenue from operations reached approximately ₹7,615 crore in Q2 FY27, compared with ₹6,189 crore in the same quarter last year. This reflects strong demand across the company’s healthcare services and related businesses.

Net profit increased to approximately ₹630 crore from ₹477 crore last year. The 32% improvement shows that Apollo converted its growing revenue into higher earnings rather than allowing operating expenses to absorb the entire increase.

The results were also broadly in line with market expectations. Analysts surveyed by LSEG had estimated an average profit of approximately ₹636 crore, meaning the reported figure was slightly below that forecast despite strong annual growth.

Operating performance provided another encouraging signal. EBITDA increased 29% to approximately ₹1,191 crore from ₹924 crore last year, indicating that earnings from regular business operations grew faster than revenue.

The EBITDA margin improved to 15.6% from 14.9%. This means Apollo generated approximately ₹15.60 in operating earnings for every ₹100 of revenue, compared with ₹14.90 a year earlier.

The improvement continued when compared with the previous quarter. Revenue increased approximately 10%, EBITDA rose 11% and net profit grew 8%, showing that growth was not limited to the annual comparison.

The hospital business remained the main earnings driver. Healthcare services revenue reached approximately ₹3,963 crore, representing growth of more than 23% compared with the corresponding quarter last year.

Healthcare services segment profit increased to approximately ₹760 crore. This performance reflects the importance of Apollo’s established hospital network, where patient demand and specialised medical services support revenue generation.

One important factor behind the improvement was demand for complex medical procedures. Treatments involving cardiology, oncology and other specialised fields can contribute significantly to hospital revenue because they require advanced facilities and experienced medical teams.

Apollo has also benefited from efforts to improve the use of its existing hospital capacity. Higher occupancy can support profitability because hospitals must maintain infrastructure, equipment and medical staff even when some beds remain unused.

However, occupancy is only one part of the picture. The types of treatments performed and the average revenue generated per patient also influence hospital earnings, making specialised healthcare services important for long term growth.

The retail health and diagnostics business also expanded. Segment revenue reached approximately ₹429 crore, representing growth of around 19.5% compared with the same quarter last year.

This business includes healthcare services delivered outside traditional hospital admissions, such as diagnostics and outpatient care. Its expansion helps Apollo serve patients through a wider network rather than depending entirely on hospital stays.

Digital health and pharmacy distribution delivered another substantial contribution. Revenue reached approximately ₹3,286 crore, increasing 23.5% from the previous year.

The segment generated profit of approximately ₹173 crore, highlighting how pharmacy distribution and digital healthcare have become important parts of Apollo’s wider business model.

The combination of hospitals, pharmacies and digital services gives Apollo several opportunities to serve patients. Someone receiving hospital treatment may also require diagnostic tests, medicines and follow up consultations through other parts of the network.

Apollo is simultaneously investing in additional hospital capacity. The company previously outlined plans to add more than 5,800 beds over five years, reflecting its expectation of sustained demand for specialised healthcare services.

Expansion creates opportunities, but new hospitals also involve substantial costs. Facilities require equipment, staffing and operating expenditure before patient volumes reach mature levels, which can temporarily affect profitability.

That makes the performance of recently opened hospitals particularly important. Investors will be watching how quickly new facilities attract patients, improve occupancy and begin contributing positively to operating earnings.

The latest results suggest that Apollo’s established operations are generating enough momentum to support continued investment. Nevertheless, maintaining margins while expanding the hospital network will require careful cost management and efficient use of capacity.

Apollo Hospitals enters the second half of FY27 with strong revenue growth, improving operating margins and expanding healthcare businesses. The next results will show whether specialised treatment demand remains strong and whether new hospitals can begin contributing meaningfully without placing excessive pressure on profitability.